List of works - Paresh Dandona

Addition of glucagon-like peptide-1 receptor agonist therapy to insulin in C-peptide-positive patients with type 1 diabetes

scientific article published on 08 January 2019

Bariatric Surgery: Remission of Inflammation, Cardiometabolic Benefits, and Common Adverse Effects

scientific article published on 04 August 2020

Dapagliflozin in patients with type 1 diabetes: A post hoc analysis of the effect of insulin dose adjustments on 24-hour continuously monitored mean glucose and fasting β-hydroxybutyrate levels in a phase IIa pilot study

scientific article published on 18 January 2017

Decreases in neprilysin and vasoconstrictors and increases in vasodilators following bariatric surgery

scientific article published on 13 April 2018

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial

scientific article published on 19 July 2018

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study

scientific article published on 23 October 2018

Glucose Variables in Type 1 Diabetes Studies With Dapagliflozin: Pooled Analysis of Continuous Glucose Monitoring Data From DEPICT-1 and -2

scientific article published on 09 April 2019

Hypogonadotropic Hypogonadism in Men With Diabesity

scientific article published on 01 July 2018

Increase in Osteocalcin Following Testosterone Therapy in Men With Type 2 Diabetes and Subnormal Free Testosterone

scientific article published on 01 July 2019

Incretins: Beyond type 2 diabetes.

scientific article

International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium–Glucose Cotransporter (SGLT) Inhibitors

scientific article published on 06 February 2019

Intranasal Insulin Administration Does Not Affect LH Concentrations in Men with Diabetes

Liraglutide Treatment in Overweight and Obese Patients with Type 1 Diabetes: A 26 weeks Randomized Controlled Trial

scientific article published on 19 May 2020

Liraglutide acutely suppresses glucagon, lipolysis and ketogenesis in type 1 diabetes